A newly-approved Novartis drug combination showed impressive efficacy in reducing cardiac death and morbidity from congestive heart failure, one of the most common ailments taking the lives and health of America s senior population.
A new drug combination appears to reduce the toll of heart failure by almost one-fifth. Some caveats warrant attention, but for such a common, lethal condition, this therapy may change the standard of care if confirmed.
